Abbott Developing CDx for Merck Investigational Cancer Drug | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Abbott said today it will provide a companion diagnostic for an investigational cancer therapy being developed by Merck.

Under the terms of the deal, Abbott will use its fluorescence in situ hybridization technology to develop a test to identify deletions of the TP53 gene in cancer patients. The assay will be evaluated in clinical trials for its ability to select the most appropriate patients for Merck's therapy.

Other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.